NVCT Key Statistics, Chart & Performance
The current stock price of NVCT is 6.09 USD. In the past month the price decreased by -6.02%. In the past year, price increased by 23.81%.
NVCT Latest News, Press Relases and Analysis
NVCT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.76 | 396.78B | ||
| AMGN | AMGEN INC | 15.49 | 182.47B | ||
| GILD | GILEAD SCIENCES INC | 15.19 | 154.34B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.57 | 108.22B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.8 | 79.48B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 888.34 | 59.85B | ||
| INSM | INSMED INC | N/A | 45.04B | ||
| NTRA | NATERA INC | N/A | 32.59B | ||
| BIIB | BIOGEN INC | 10.59 | 26.01B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.2 | 20.68B | ||
| INCY | INCYTE CORP | 15.9 | 20.04B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.22B |
Related stock screener links
About NVCT
Company Profile
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is headquartered in Fort Lee, New Jersey and currently employs 13 full-time employees. The company went IPO on 2022-02-04. The firm is developing two drug candidates: NXP800 and NXP900. NXP800 is a small molecule GCN2 activator, which is in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP800 activates the GCN2 kinase inducing inhibition of cap-dependent protein translation and activation of the integrated stress response leading to cancer cell death. NXP900 is a targeted-therapy, small molecule drug candidate that inhibits the proto-oncogene c-Src (SRC) and YES1 kinases, which is undergoing a Phase 1a dose escalation study. SRC is aberrantly activated in many cancer types, including solid tumor cancers such as breast, colon, prostate, pancreatic and ovarian cancers.
Company Info
NUVECTIS PHARMA INC
1 Bridge Plaza, 2nd Floor
Fort Lee NEW JERSEY US
Employees: 13
Phone: 13608377232
NUVECTIS PHARMA INC / NVCT FAQ
What does NUVECTIS PHARMA INC do?
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is headquartered in Fort Lee, New Jersey and currently employs 13 full-time employees. The company went IPO on 2022-02-04. The firm is developing two drug candidates: NXP800 and NXP900. NXP800 is a small molecule GCN2 activator, which is in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP800 activates the GCN2 kinase inducing inhibition of cap-dependent protein translation and activation of the integrated stress response leading to cancer cell death. NXP900 is a targeted-therapy, small molecule drug candidate that inhibits the proto-oncogene c-Src (SRC) and YES1 kinases, which is undergoing a Phase 1a dose escalation study. SRC is aberrantly activated in many cancer types, including solid tumor cancers such as breast, colon, prostate, pancreatic and ovarian cancers.
What is the stock price of NUVECTIS PHARMA INC today?
The current stock price of NVCT is 6.09 USD. The price decreased by -2.4% in the last trading session.
What is the dividend status of NUVECTIS PHARMA INC?
NVCT does not pay a dividend.
What is the ChartMill rating of NUVECTIS PHARMA INC stock?
NVCT has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting NVCT stock to perform?
12 analysts have analysed NVCT and the average price target is 18.53 USD. This implies a price increase of 204.27% is expected in the next year compared to the current price of 6.09.
Would investing in NUVECTIS PHARMA INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NVCT.
What is the next earnings date for NVCT stock?
NUVECTIS PHARMA INC (NVCT) will report earnings on 2026-02-23, before the market open.
NVCT Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to NVCT. When comparing the yearly performance of all stocks, NVCT is one of the better performing stocks in the market, outperforming 73.08% of all stocks.
NVCT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NVCT. While NVCT has a great health rating, there are worries on its profitability.
NVCT Financial Highlights
Over the last trailing twelve months NVCT reported a non-GAAP Earnings per Share(EPS) of -1.26. The EPS decreased by -8.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -81.7% | ||
| ROE | -129.76% | ||
| Debt/Equity | 0 |
NVCT Forecast & Estimates
12 analysts have analysed NVCT and the average price target is 18.53 USD. This implies a price increase of 204.27% is expected in the next year compared to the current price of 6.09.